Jiangsu Recbio Technology Co Ltd (HKSE:02179) Share Price

Company Profile

Business description
Jiangsu Recbio Technology Co Ltd is a vaccine company focused on the research, development, and commercialization of vaccines, with a high-value vaccine portfolio driven by in-house technologies. It has built three vaccine technology platforms: novel adjuvants, protein engineering, and immune evaluation. The company's portfolio currently consists of various vaccines, covering diseases such as cervical cancer, herpes zoster, and respiratory syncytial virus. It has two core strategic products, namely REC610, a novel adjuvanted recombinant shingles vaccine, which is currently in the stage of marketing application in China, and REC603, a recombinant HPV 9-valent vaccine under phase three clinical trial.
Contact
No. 888 Yaocheng Avenue
Medical High-tech District
Jiangsu Province
Taizhou
CHN
T: +86 52386818860
https://www.recbio.cn
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
466

Recommended

This REIT remains undervalued as trophy properties shine through.

Yingqi Tan, CFA | 01 July 2026

Why earnings growth might be more important when assessing frothy market conditions.

Damien Klassen | 30 June 2026

This company is unlikely to be disrupted by AI

Roy Van Keulen | 30 June 2026

Index	Last price	Change	% Change
All Ordinaries	8,931.40	71.60	-0.80%
CAC 40	8,337.29	66.70	-0.79%
DAX 40	25,040.28	44.47	0.18%
Dow JONES (US)	52,305.24	13.96	-0.03%
FTSE 100	10,478.34	18.78	-0.18%
HKSE	22,881.02	145.66	-0.63%
NASDAQ	26,040.03	173.69	-0.66%
Nikkei 225	70,474.96	412.64	0.59%
NZX 50 Index	13,610.50	11.16	-0.08%
S&P 500	7,483.23	16.13	-0.22%
S&P/ASX 200	8,722.90	71.70	-0.82%
SSE Composite Index	4,094.40	20.50	0.50%